Samsung Bioepis' SB27 Biosimilar Meets Key Endpoints in NSCLC Trials
Event summary
- Samsung Bioepis' SB27, a proposed biosimilar to Keytruda (pembrolizumab), met primary endpoints in Phase 1 and Phase 3 trials for non-small cell lung cancer (NSCLC).
- Phase 1 trial demonstrated pharmacokinetic bioequivalence of SB27 to both EU- and US-sourced Keytruda in stage II-IIIA NSCLC patients.
- Phase 3 trial showed equivalent objective response rate (ORR) at Week 24 for metastatic non-squamous NSCLC, with safety profiles comparable to Keytruda.
The big picture
Samsung Bioepis' positive Phase 1 and Phase 3 results for SB27 reinforce its position as a key player in the biosimilars market. The success of this pembrolizumab biosimilar comes at a time when immune checkpoint inhibitors are central to cancer treatment, and biosimilars are increasingly seen as tools to reduce healthcare costs without compromising patient outcomes.
What we're watching
- Regulatory Approval Pathway
- The pace at which SB27 advances through regulatory approvals will determine its market entry timeline and competitive positioning against Keytruda.
- Market Adoption Dynamics
- Whether oncologists and payers will rapidly adopt SB27 as a cost-effective alternative to Keytruda, given proven equivalence in efficacy and safety.
- Pipeline Expansion Strategy
- How Samsung Bioepis leverages this success to accelerate its broader biosimilar portfolio, particularly in high-value therapeutic areas like oncology.